Recent News

10 Biggest Pharmaceutical Settlements

As consumers, we trust that the pharmaceuticals we take are safe and effective. Unfortunately, that is not always the case. Throughout the course of history, many large pharmaceutical companies have reached substantial settlements with individuals and their families after some pharmaceuticals were found to have harmful and unforeseen side effects. Here, the pharmaceutical liability attorneys…

Read More...

Updates on Allergan Breast Implants Class Claim

In July 2019, pharmaceutical manufacturer Allergan ordered a recall of its BIOCELL textured breast implants after reports that the implants were linked to a serious cancer affecting hundreds of patients. Here, the pharmaceutical liability attorneys at Peter Angelos Law discuss recent updates to this serious event as well as your legal options if you have…

Read More...

Mercury-Containing Dental Amalgam May Have Harmful Health Effects to High-Risk Groups

On September 24th, 2020, the FDA published a press release issuing updated recommendations regarding the potential risks of mercury-containing dental amalgam fillings to high-risk groups. The FDA is issuing these updates as a response to certain risks surrounding the dental fillings that may predominantly impact certain high-risk groups.    Dental Amalgam is a Substance Used…

Read More...

FDA News Release: Opdivo and Yervoy Combination Approved to Treat Mesothelioma

For the first time in 16 years, a drug combination and FDA-approved systemic therapy has been approved to treat malignant pleural mesothelioma that cannot be removed surgically. The first-line treatment for adults will include drug combination therapy using Opdivo (nivolumab) and Yervoy (ipilimumab) to increase the chances of patient survival. Here, the pharmaceutical liability attorneys…

Read More...

Recent FDA News Release: Benzodiazepines Boxed Warning to Be Updated to Include Serious Risks

On September 23rd, the U.S. Food and Drug Administration (FDA) announced that it would be requiring “class-wide labeling changes” for psychoactive drugs that fall under the class of Benzodiazepines. The label change to the Boxed Warning will include benzos’ risks of abuse, dependence, misuse, addiction and potential withdrawal symptoms.  The labeling update is a reaction…

Read More...

FDA Requests Removal of Zantac From the Market Immediately

On April 1st, the Food and Drug Administration (FDA) announced its request for all prescription and over-the-counter ranitidine drugs to be removed from the market immediately. This decision was made based on an ongoing investigation of possible carcinogenic effects of the contaminant N-nitrosodimethylamine, or NDMA. Here, the pharmaceutical liability attorneys at Peter Angelos Law discuss…

Read More...

Zantac Manufacturer Recalls Medication Due to Confirmed Contamination

Sandoz Inc. has voluntarily recalled the generic version of common medication Zantac after the medication was confirmed to be contaminated with a human carcinogen. Here, the pharmaceutical liability attorneys at The Law Offices of Peter Angelos discuss the updates to the ongoing Zantac claims.  Global health regulators recently raised concerns about the possibility that the…

Read More...

Carcinogen Found in Stomach Drug Leads to Halt in Distribution

Global health regulators have raised the alarm about the possibility that the widely used drug, Zantac, could be tainted with the same cancer-causing agent found in Valsartan earlier this year. Here, the pharmaceutical liability attorneys at The Law Offices of Peter Angelos detail the preliminary results of the FDA and EU probes. Officials are Investigating…

Read More...

Updates on Link Between Flesh-Eating Genital Infection and Diabetes Drug SGLT2 Inhibitors

A recent study investigated a potential link between a Type-2 diabetes drug and a severe and potentially fatal necrotizing fasciitis called Fournier gangrene. Here, the pharmaceutical liability attorneys at The Law Offices of Peter Angelos discuss the recent study and how SGLT2 inhibitors may potentially be linked to the development of Fournier gangrene. The First…

Read More...

FDA Includes Black Box Warning on Gout Medicine Uloric

As of February 2019, the U.S. Food and Drug Administration has stated that there is a higher risk of death associated with gout medicine Uloric (febuxostat) compared to other gout medicines. The FDA has now included a Black Box Warning for Uloric as a result of the recent findings. Here, the pharmaceutical liability attorneys at…

Read More...